Literature DB >> 10418915

Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine.

C Boursaux-Eude1, S Thiberge, G Carletti, N Guiso.   

Abstract

When pertussis toxin S1 subunit and pertactin structural genes in Bordetella pertussis clinical isolates from France and Germany were sequenced, 3 previously described S1 subunit types (S1 A, B and E), and 4 pertactin types (PRN A, B, C, A*) were found. PRN A*, present in the WHO reference strain 18323, was not described previously. In a respiratory mouse model, a tricomponent acellular pertussis vaccine (Infanrix) was highly effective in promoting lung clearance of all isolates expressing different S1 subunit and pertactin suggesting that use of acellular vaccine will not increase the risks of pertussis infection by these B. pertussis variants.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10418915     DOI： 10.1016/s0264-410x(99)00038-9

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  24 in total

1.  Role of adhesins and toxins in invasion of human tracheal epithelial cells by Bordetella pertussis.

Authors:  L Bassinet; P Gueirard; B Maitre; B Housset; P Gounon; N Guiso
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

2.  Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years.

Authors:  C Weber; C Boursaux-Eude; G Coralie; V Caro; N Guiso
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

3.  Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom.

Authors:  N K Fry; S Neal; T G Harrison; E Miller; R Matthews; R C George
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

4.  Strain variation among Bordetella pertussis isolates from Québec and Alberta provinces of Canada from 1985 to 1994.

Authors:  Mark S Peppler; Sharee Kuny; Anna Nevesinjac; Christina Rogers; Yvon R de Moissac; Kathleen Knowles; Manon Lorange; Gaston De Serres; James Talbot
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

5.  Antigenic divergence suggested by correlation between antigenic variation and pulsed-field gel electrophoresis profiles of Bordetella pertussis isolates in Japan.

Authors:  Atsuko Kodama; Kazunari Kamachi; Yoshinobu Horiuchi; Toshifumi Konda; Yoshichika Arakawa
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

6.  Polymorphisms of the fimbria fim3 gene of Bordetella pertussis strains isolated in Canada.

Authors:  Raymond S W Tsang; Allan K H Lau; Michelle L Sill; Scott A Halperin; Paul Van Caeseele; Frances Jamieson; Irene E Martin
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

Review 7.  Bordetella pertussis: the intersection of genomics and pathobiology.

Authors:  Andrew Preston
Journal:  CMAJ       Date:  2005-07-05       Impact factor: 8.262

8.  Significant gene order and expression differences in Bordetella pertussis despite limited gene content variation.

Authors:  Mary M Brinig; Craig A Cummings; Gary N Sanden; Paola Stefanelli; Andrew Lawrence; David A Relman
Journal:  J Bacteriol       Date:  2006-04       Impact factor: 3.490

9.  Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model.

Authors:  Eiji Komatsu; Fuminori Yamaguchi; Akio Abe; Alison A Weiss; Mineo Watanabe
Journal:  Clin Vaccine Immunol       Date:  2010-03-31

10.  Bordetella species are distinguished by patterns of substantial gene loss and host adaptation.

Authors:  C A Cummings; M M Brinig; P W Lepp; S van de Pas; D A Relman
Journal:  J Bacteriol       Date:  2004-03       Impact factor: 3.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.